Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

INTRODUCTION: This integrated analysis describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, at 15 and 30 mg once daily for up to 3 years of exposure in patients with active psoriatic arthritis (PsA) who had a prior inadequate response or intolerance to ≥ 1 non-biologic or bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Burmester, Gerd R., Winthrop, Kevin, Blanco, Ricardo, Nash, Peter, Goupille, Philippe, Azevedo, Valderilio F., Salvarani, Carlo, Rubbert-Roth, Andrea, Lesser, Elizabeth, Lippe, Ralph, Lertratanakul, Apinya, Mccaskill, Reva M., Liu, John, Ruderman, Eric M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717827/
https://www.ncbi.nlm.nih.gov/pubmed/34970731
http://dx.doi.org/10.1007/s40744-021-00410-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717827/
https://www.ncbi.nlm.nih.gov/pubmed/34970731
http://dx.doi.org/10.1007/s40744-021-00410-z

Ejemplares similares